{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:39:39Z","timestamp":1795081179399,"version":"4.10.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41591-025-03738-z","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T13:01:43Z","timestamp":1748696503000},"page":"2806-2814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7760-4724","authenticated-orcid":false,"given":"Thomas B.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-9378","authenticated-orcid":false,"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1264-5327","authenticated-orcid":false,"given":"Joan","family":"Palou Redorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0391-2342","authenticated-orcid":false,"given":"Ja Hyeon","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kretkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Alekseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-3780","authenticated-orcid":false,"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-3465","authenticated-orcid":false,"given":"F\u00e9lix","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Calella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossano","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Eccleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabete","family":"Michelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8729-8652","authenticated-orcid":false,"given":"Jennifer","family":"Vermette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caimiao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"3738_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"3738_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein, J. M. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 Amendment. J. Urol. 211, 533\u2013538 (2024).","journal-title":"J. Urol."},{"key":"3738_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero, P. et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 Guidelines Update. Eur. Urol. 86, 531\u2013549 (2024).","journal-title":"Eur. Urol."},{"key":"3738_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3390\/cells11030357","volume":"11","author":"A Audisio","year":"2022","unstructured":"Audisio, A. et al. New perspectives in the medical treatment of non-muscle-invasive bladder cancer: immune checkpoint inhibitors and beyond. Cells 11, 357 (2022).","journal-title":"Cells"},{"key":"3738_CR5","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar, A. V. et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 22, 919\u2013930 (2021).","journal-title":"Lancet Oncol."},{"key":"3738_CR6","unstructured":"US Food and Drug Administration. Keytruda. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125514s110lbl.pdf"},{"key":"3738_CR7","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1158\/1538-7445.AM2017-2667","volume":"77","author":"S Youssef","year":"2017","unstructured":"Youssef, S. et al. Abstract 2667: In vitro properties and pre-clinical activity of PF-06801591, a high-affinity engineered anti-human PD-1. Cancer Res. 77, 2667 (2017).","journal-title":"Cancer Res."},{"key":"3738_CR8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/jamaoncol.2019.0836","volume":"5","author":"ML Johnson","year":"2019","unstructured":"Johnson, M. L. et al. Assessment of subcutaneous vs intravenous administration of anti\u2013PD-1 antibody PF-06801591 in patients with advanced solid tumors. JAMA Oncol. 5, 999\u20131007 (2019).","journal-title":"JAMA Oncol."},{"key":"3738_CR9","doi-asserted-by":"publisher","first-page":"S721","DOI":"10.1016\/j.annonc.2020.08.1175","volume":"31","author":"BCC Cho","year":"2020","unstructured":"Cho, B. C. C. et al. 1055P Updated results of subcutaneous (SC) anti-programmed cell death 1 (PD-1) receptor antibody PF-06801591 for locally advanced or metastatic non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC). Ann. Oncol. 31, S721 (2020).","journal-title":"Ann. Oncol."},{"key":"3738_CR10","doi-asserted-by":"publisher","first-page":"34066","DOI":"10.18632\/oncotarget.26122","volume":"9","author":"A Hashizume","year":"2018","unstructured":"Hashizume, A. et al. Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. Oncotarget 9, 34066\u201334078 (2018).","journal-title":"Oncotarget"},{"key":"3738_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/cancers16071356","volume":"16","author":"M Maas","year":"2024","unstructured":"Maas, M. et al. PD-L1 expression in high-risk non-muscle-invasive bladder cancer is influenced by intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) therapy. Cancers (Basel) 16, 1356 (2024).","journal-title":"Cancers (Basel)"},{"key":"3738_CR12","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/OTT.S165840","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Bacillus Calmette\u2013Gu\u00e9rin and anti-PD-L1 combination therapy boosts immune response against bladder cancer. Onco Targets Ther. 11, 2891\u20132899 (2018).","journal-title":"Onco Targets Ther."},{"key":"3738_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116203","volume":"171","author":"JW Cui","year":"2024","unstructured":"Cui, J. W. et al. Tumor immunotherapy resistance: revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape. Biomed. Pharmacother. 171, 116203 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"3738_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba, D., Rodrigues, G., Myles, J., Zee, B. & Pater, J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16, 139\u2013144 (1998).","journal-title":"J. Clin. Oncol."},{"key":"3738_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/BF00439229","volume":"5","author":"MT King","year":"1996","unstructured":"King, M. T. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual. Life Res. 5, 555\u2013567 (1996).","journal-title":"Qual. Life Res."},{"key":"3738_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euros.2022.02.011","volume":"39","author":"NC Grossmann","year":"2022","unstructured":"Grossmann, N. C. et al. Comparative outcomes of primary versus recurrent high-risk non\u2013muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study. Eur. Urol. Open Sci. 39, 14\u201321 (2022).","journal-title":"Eur. Urol. Open Sci."},{"key":"3738_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.21037\/tau-20-960","volume":"10","author":"J Tian","year":"2021","unstructured":"Tian, J. et al. Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy? Transl. Androl. Urol. 10, 356\u2013373 (2021).","journal-title":"Transl. Androl. Urol."},{"key":"3738_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","volume":"27","author":"SP Lerner","year":"2009","unstructured":"Lerner, S. P. et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol. Oncol. 27, 155\u2013159 (2009).","journal-title":"Urol. Oncol."},{"key":"3738_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrurol.2015.58","volume":"12","author":"AM Kamat","year":"2015","unstructured":"Kamat, A. M. et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat. Rev. Urol. 12, 225\u2013235 (2015).","journal-title":"Nat. Rev. Urol."},{"key":"3738_CR20","doi-asserted-by":"publisher","unstructured":"Gerald, T. et al. Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.015 (2025).","DOI":"10.1016\/j.urolonc.2025.01.015"},{"key":"3738_CR21","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.3390\/jcm13082182","volume":"13","author":"F Sanguedolce","year":"2024","unstructured":"Sanguedolce, F. et al. Integrating the PD-L1 prognostic biomarker in non-muscle invasive bladder cancer in clinical practice\u2014a comprehensive review on state-of-the-art advances and critical issues. J. Clin. Med. 13, 2182 (2024).","journal-title":"J. Clin. Med."},{"key":"3738_CR22","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3738_CR23","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/cncr.33457","volume":"127","author":"PJ Voon","year":"2021","unstructured":"Voon, P. J., Cella, D. & Hansen, A. R. Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies. Cancer 127, 1360\u20131368 (2021).","journal-title":"Cancer"},{"key":"3738_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102706","volume":"9","author":"F Cappuzzo","year":"2024","unstructured":"Cappuzzo, F. et al. 244MO Primary results from IMscin002: a study to evaluate patient (pt)- and healthcare professional (HCP)-reported preferences for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC. ESMO Open 9, 102706 (2024).","journal-title":"ESMO Open"},{"key":"3738_CR25","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1200\/JCO.23.00307","volume":"41","author":"AM Kamat","year":"2023","unstructured":"Kamat, A. M. et al. Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J. Clin. Oncol. 41, 5437\u20135447 (2023).","journal-title":"J. Clin. Oncol."}],"updated-by":[{"DOI":"10.1038\/s41591-025-03894-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03738-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03738-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03738-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:57:38Z","timestamp":1762257458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03738-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3738"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03738-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Supplementary Information published online was an earlier, incorrect version and has now been replaced in the online version of the article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-025-03894-2","URL":"https:\/\/doi.org\/10.1038\/s41591-025-03894-2","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.D.S. reports research\/consulting: Allessa, Amgen, Artera, Astellas, AstraZeneca, Aura Biosciences, Bayer, Bristol Myers Squibb, Caris, CG Oncology, Daiichi Sankyo, Dendreon, Glytheryx, Invitae, Janssen, MDxhealth, Merck, Minomic, Novartis, Nusano, PhotoCure, Pfizer, Sumitomo, Telix, Tolmar, Tutelix and Urogen. T.B.P. reports honoraria: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elexis, Gilead, Incyte, Ipsen, Johnson & Johnson, Mashup, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seagen; consulting or advisory role: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elexis, Gilead, Incyte, Ipsen, Johnson & Johnson, Mashup, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seagen; research funding: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elexis, Incyte, Ipsen, Johnson & Johnson, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche and Seagen; and travel, accommodations or expenses: Astellas, AstraZeneca, Gilead, Ipsen, Merck Sharp & Dohme, Pfizer and Roche. J. Bedke reports financial interests from Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Ipsen, Janssen, Merck Sorono, Merck Sharp & Dohme, Pfizer, Roche, Nektar, Novartis and Seagen and membership in the European Association of Urology and the Renal Cell Carcinoma Guidelines Panel (Vice-Chairman). M.D.G. reports stock and other ownership interests: Pfizer, Merck and Gilead Sciences; research funding: Merck, Bristol Myers Squibb, Mirati Therapeutics, Seagen, Alliance Foundation Trials, Alliance for Clinical Trials in Oncology, Clovis Oncology, Arvinas, ALX Oncology, Hoosier Cancer Research Network, Novartis, Acrivon Therapeutics, Astellas, Genentech, Accuray, PCCTC, G1 Therapeutics, OncoC4, Flare Therapeutics, Loxo\/Lilly, Roche and Pfizer; other relationships: Elsevier, Medscape and Research to Practice; uncompensated relationships: G1 Therapeutics and Loxo\/Lilly. J.P.R. reports advisory\/consultancy roles for Arquer Diagnostics, Biotech, BTA Pharmaceuticals, Combat, Genomic Expression and Olympus; steering committee membership for AstraZeneca, Bristol Myers Squibb, Janssen and Pfizer; grant or research support from Arquer Diagnostics, Biotech, BTA Pharmaceuticals, Cepheid, TARIS Biomedical and Nucleix; and research funding from Pfizer. J.H.K. reports research funding from Pfizer. M.K. reports research funding from Pfizer. E.X. reports consulting or advisory role: Pfizer, Ferring and Boston Scientific and research funding: Ferring and Pfizer. B.A. reports honoraria: AstraZeneca, Astellas, Eisai, Janssen, Bayer, Merck Sharp & Dohme, Merck, Pfizer, Roche and Bristol Myers Squibb; consulting or advisory role: AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Janssen, Merck, Pfizer, Merck Sharp & Dohme, Roche and Eisai; speakers\u2019 bureau: Janssen, Astellas, Pfizer, AstraZeneca, Bayer, Merck, Bristol Myers Squibb, Merck Sharp & Dohme, Eisai and Roche; research funding: AstraZeneca, Merck, Bayer, Astellas, Janssen, Bristol Myers Squibb, Pfizer, ICON Clinical Research, Eisai, Merck Sharp & Dohme and Roche; and travel, accommodations and expenses: AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Janssen, Merck Sharp & Dohme, Pfizer and Sanofi. D.Y. reports research funding from Pfizer. F.G.-R. reports research support\/principal investigator: Johnson & Johnson, Pfizer, Taris, Bristol Myers Squibb, Roche, Seagen, AstraZeneca, Combat Medical, Cepheid, Fidia, Astellas, UroGen and Merck Sharp & Dohme; employment: SERMAS (Servicio Madrile\u00f1o de Salud); consultancy: Johnson & Johnson, Pfizer, Merck, Roche, Taris, Combat Medical, AstraZeneca, Merck Sharp & Dohme and Bristol Myers Squibb; stockholder: CG Oncology; speakers\u2019 bureau: Janssen, Nucleix, Merck Sharp & Dohme, Pfizer, Merck, Bristol Myers Squibb, AstraZeneca, Palex, Combat Medical, Johnson & Johnson and Recordati; travel: Pfizer, Recordati, Ipsen, Combat Medical, Alter, Salvat, Nucleix, AstraZeneca, Fidia and Johnson & Johnson; advisory board: AstraZeneca, Bristol Myers Squibb, Combat Medical, Johnson & Johnson, Nucleix, Pfizer, Taris, Roche and Merck Sharp & Dohme; and manuscript support: Pfizer, Janssen, Combat Medical, AstraZeneca, Johnson & Johnson and Bristol Myers Squibb. A.B. reports consulting or advisory role: Astellas, Janssen-Cilag, OPKO Health, MDxHealth, Ferring, Bayer, AstraZeneca, Hauora and Pfizer; speakers\u2019 bureau: Astellas; and research funding: Sandoz-Novartis, Merck Sharp & Dohme and Pfizer. G.S.K. reports honoraria: AbbVie, Tersera, Bayer, Knight Pharmaceuticals, AstraZeneca Canada and PhotoCure; consulting or advisory role: Merck, Theralase, Janssen Oncology, Ferring, Verity Pharmaceuticals, Bristol Myers Squibb, EMD Serono, Pfizer, Novartis and enGene; research funding: Johnson & Johnson\/Janssen and Pfizer. J. Brinkmann reports employment: Pfizer Pharma GmbH. A.-M.C. reports employment: Pfizer SRL. R.C. reports employment: Pfizer SRL. A.E. reports employment: Pfizer Ltd. E.M. reports employment: Pfizer Inc. J.V. reports employment: Pfizer Inc. C.W. reports employment: Pfizer Inc. G.D.S. reports advisory\/consultancy roles: Heat Biologics, CG Oncology, PhotoCure, Merck, Roche\/Genentech, Ciclomed, Taris Biomedical (now Janssen), MDxHealth, Fidia Farmaceutici, UroGen, Ferring, Aduro, Boston Scientific, Bristol Myers Squibb, AstraZeneca, Pfizer, Janssen, Epivax Therapeutics, Natera, FKD, EnGene Bio, Sesen Bio, BioCanCell (now Archiano), Nucleix, Ipsen, Combat Medical, Astellas, FerGene, Dendreon, AbbVie, Seagen, Verity Pharmaceuticals, Regeneron, STIMIT, Vyriad, Protara, xCures, Nonagen, Nanology and Imvax; clinical trial protocol committee membership for Bristol Myers Squibb, CG Oncology, Fidia, Janssen, Merck, Pfizer, PhotoCure, Protara and Seagen; stock\/shares in CG Oncology, EnGene Bio, EpiVax Therapeutics and UroGen; and research funding from Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}